Big-bracket investments push states to create social infrastructureFurthermore, Ferdinand's comments shed light on the broader issue of financial management and decision-making within top football clubs. The disparity between player salaries and staff wages highlights the skewed priorities of many organizations, where exorbitant sums are spent on a select few while the majority are left to bear the brunt of cost-cutting measures.Noneroulette payout chart 。

A campground is expanding with 43 new hotel rooms and 18 homes, all built by a massive 3D printer. Leaders from two of the nation's top construction trade groups told Fox News Digital they are looking forward to the new Trump administration with hopes their industry will be burdened by fewer regulations and policies enacted under President Biden that they said stymied additional growth in their sector. On Monday, the Biden administration touted the addition of 1.6 million new construction and manufacturing jobs. However, Ben Brubeck, vice president of regulatory affairs for the Associated Builders and Contractors, cautioned that beneath this seemingly big announcement, "the growth can be much better if we're in the right economic and policy environment." Brubeck said his association's members have broadly indicated disappointment at the opportunities available to them under various Biden administration programs, including the Infrastructure Investment and Jobs Act (IJA), the CHIPS and Science Act (CHIPS), the Inflation Reduction Act (IRA) and the American Rescue Plan Act (ARPA). "We survey our members on a pretty regular basis, and the number of members who reported participation in the IJA- and CHIPS- and IRA- and ARPA-funded projects has been pretty — it's been low," Brubeck said. "It's been less than expected." WHITE HOUSE INSISTS BIDEN, HARRIS HAVE ‘ONE OF MOST SUCCESSFUL ADMINISTRATIONS IN HISTORY’ DESPITE 2024 LOSS Carpenters frame a roof on a new home under construction in Nesconset, N.Y., Feb. 6, 2018. (John Paraskevas/Newsday RM vis Getty Images) Brubeck pointed to the fact that it has taken a long time for the money from these programs to be disbursed due to burdensome regulations, such as permitting requirements. He also pointed to oppressive labor policies, such as project labor agreements and increased borrowing costs as other elements that have added to less growth than could have been seen otherwise under President Biden. Brian Turmail, the vice president of public affairs and workforce for the Associated General Contractors of America, also noted the failure of Biden's major construction investments due to regulations and review processes. BIDEN ADMIN AIMS TO PUSH TOWNS, CITIES TO ADOPT GREEN ENERGY BUILDING CODES: ‘VERY SUSPICIOUS’ President Biden speaks with members of Ironworkers Local 5 after signing an executive order on project labor agreements at the union's training hall Feb. 4, 2022, in Upper Marlboro, Md. (Getty Images) "Our analysis is [the Biden administration] kind of got in their own way affecting the market, because they couldn't help themselves but to put in so many kinds of social and environmental rules on top of their funding that they slowed down the progress they so desperately wanted to see," Turmail said. He also pointed out that the administration "put a lot of new strings" on semiconductor plant construction that has stymied growth. Turmail and Brubeck said they have hopes growth in the construction sector will ramp up under the Trump administration as companies manage their way through federal requirements enacted under Biden and see others potentially rolled back. I HAD A JOB ON THE KEYSTONE XL PIPELINE UNTIL BIDEN FIRED ME TO SATISFY CLIMATE EXTREMISTS President Biden was widely criticized for his "garbage" remark about former President Trump's supporters. (Getty Images) "The irony is that, by the time President Trump comes back into office, we do anticipate a big bump up in infrastructure construction," Turmail said. "Because all those projects where they've announced funding over the last two to three years will finally clear their environmental hurdle and begin construction." CLICK HERE TO GET THE FOX NEWS APP "Our federal contractors are completely on the sidelines right now for these large-scale projects, and this all started at the beginning of the year in January," Brubeck added. "So, they're really excited for the potential of regulatory relief on the horizon as a result of the Trump administration coming in." The White House did not provide Fox News Digital with an on-the-record comment in time for publication.

HERZLIYA, Israel and CALGARY, AB , Nov. 26, 2024 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to report positive results from a basic safety assessment study, evaluating LPT-CBD administered as a single injection in Göttingen minipigs. The drug was administered in three ascending doses, and the animals were closely monitored over a 28-day period for key safety parameters. These included clinical observations, vital signs, blood parameters, and local injection site reactions. Encouragingly, no adverse events were recorded during the study. All animals exhibited normal weight gain and demonstrated excellent tolerance to the drug, with no local reactions observed at any of the administered dose sites. Minipigs are breeds of miniature domestic pigs which are recognized by the FDA as a robust translational model due to their anatomical, physiological, and biochemical similarities to humans. They provide valuable insights into pharmacokinetics, toxicity, and drug efficacy. "We are thrilled that LPT-CBD once again demonstrates a promising safety profile, particularly in minipigs, which are widely regarded as a strong toxicology model," said Prof. Chezy Barenholz, Chief Scientific Officer of Innocan Pharma. Dr. Eyal Kalo , Innocan's R&D Director, added: "These results are immensely gratifying as they provide strong feasibility for LPT-CBD's safety evaluation, supporting our upcoming regulatory milestones and paving the way for its ultimate approval." LPT-CBD is an innovative injectable liposomal formulation designed for the sustained release of CBD, targeting the treatment of chronic pain. Previous preclinical studies in various animal models have demonstrated prolonged CBD pharmacokinetics, delivering long-term efficacy. About Innocan Pharma: Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients' quality of life. This segment involves innovative drug delivery technology: LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for Chronic Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan carries on business through subsidiary, BI Sky Global Ltd. that focuses on developing advanced targeted online sales. https://innocanpharma.com/ Contact Information: For Innocan Pharma Corporation: Iris Bincovich, CEO +1 5162104025 +972-54-3012842 +442037699377 info@innocanpharma.com NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Caution Regarding Forward-Looking Information Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedarplus.ca . Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law. Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpgAmpliTech Group Announces Closing of $1.4 Million Registered Direct OfferingIn conclusion, the Chinese Foreign Ministry's decision to impose visa restrictions on US individuals for their poor behavior in Hong Kong affairs is a necessary step to safeguard China's sovereignty and territorial integrity. It is a clear signal that China will not tolerate any external interference in its internal affairs and will take decisive action to protect its national interests. It is hoped that this move will help deter further provocations and pave the way for constructive dialogue between China and the United States.

The overwhelming support for Wu Liufang highlights the power of social media in amplifying the voices of talented individuals. With the click of a button, fans from around the world can show their appreciation and admiration for their favorite artists, creating a global community of supporters.

Scott Scheid , President and CEO, commented, "It continues to be a difficult time for the wine industry. Bulk wine prices remain depressed and the market for cased goods, which has been impacted by distributor and retailer destocking, continues to be challenging. As a company, we've made significant efforts to do more with less, highlighted by our second quarter results showing a decrease of 16% in sales and marketing expenses and a decrease of over 5% in G & A. These efforts are ongoing and I'm proud of our teams who work each day on finding opportunities for growth and ways to improve our business." Mr. Scheid continued, "We recently executed new forbearance agreements with our lenders extending through July 31, 2025 . The terms of these agreements include forbearing interest and principal payments on the Company's existing debt. In addition, under the agreement with our operating lender, the Company received an additional $5.0 million to strengthen our working capital base." Financial Results Total revenues decreased 6%, to $26.1 million for the six months ended August 31, 2024 , from $27.7 million in fiscal 2024. Cased goods sales decreased 6%, to $21.2 million in the first six months of fiscal 2025, from $22.5 million in fiscal 2024, as the bottled wine business across the entire market slowed in the first few months of calendar 2024. The Company's bulk wine sales decreased 14%, to $1.8 million from $2.1 million , and winery processing and storage revenues remained flat at $1.5 million . Gross margins remained at 20% for each period. Sales and marketing expenses decreased 16%, to $4.8 million , from $5.7 million , and general and administrative expenses decreased 5%, to $3.5 million , from $3.7 million , as the Company continues its cost-cutting efforts. During the first quarter of fiscal 2025, the Company recognized revenue of $3.6 million from proceeds received from the dissolution of a winery processing agreement. In addition, the Company recognized a gain from the sale of non-vineyard land in the amount of $1.7 million in the second quarter of fiscal 2025. Interest expense rose 150%, to $7.5 million , from $3.0 million , due to increases in interest rates as each of the Company's lenders are accruing interest at the default rate of an average of 14.3%. Earnings before interest, taxes, depreciation, and amortization (EBITDA) increased to $4.4 million , from a loss of $1.2 million , primarily from the sale of land and the proceeds from the contract dissolution. In total, the Company reported a net loss of $3.9 million for the six months ended August 31, 2024 , compared to a net loss of $4.8 million for the six months ended August 31, 2023 . About Scheid Family Wines Scheid Family Wines, a family-owned and operated wine company for over 50 years, is ranked among the top 25 largest wine producers in the United States . Based in Monterey County, California , Scheid is vertically integrated to bring high quality estate grown wines to the marketplace from its sustainably and organically certified vineyards and grower partners throughout the Central Coast. Scheid's innovative, luxury-level winery is 100% powered by renewable wind energy generated by a 400-foot-tall wind turbine, which also supplies energy to the local community. The Scheid Family Wines globally distributed brand portfolio includes Scheid Vineyards, Sunny with a Chance of Flowers, VDR (Very Dark Red), Grandeur (organically certified), Fog & Light, Metz Road, District 7, Ryder Estate, and HOXIE, a premium wine spritzer. Scheid Family Wines sells internationally to over 30 countries and is one of the largest producers of premium exclusive brands. Please visit www.scheidfamilywines.com and www.otcmarkets.com/stock/SVIN/quote for more information. View original content: https://www.prnewswire.com/news-releases/scheid-family-wines-reports-second-quarter-fiscal-2025-results-302316784.html SOURCE Scheid Family Wines( MENAFN - EIN Presswire) Plastic Healthcare Packaging Global market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033 The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports-for a limited time only! LONDON, GREATER LONDON, UNITED KINGDOM, December 16, 2024 /EINPresswire / -- The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports-limited time only! Will the Global Plastic Healthcare Packaging Market Continue to Grow? The plastic healthcare packaging market has seen strong growth in recent years, with its value set to increase from $29.91 billion in 2023 to $32.23 billion in 2024 at a compound annual growth rate CAGR of 7.8%. This growth in the historic period can be attributed to factors such as rising occurrences of respiratory diseases, increased use of plastic packaging in the healthcare industry, growing incidence of chronic disease, escalating investment in healthcare infrastructure, and an expanding geriatric population. Explore in-depth insights into the Plastic Healthcare Packaging Global Market Report with a detailed sample report: What Are the Projected Growth and Future Trends in the Plastic Healthcare Packaging Market? Strong growth is expected in the plastic healthcare packaging market in the next few years, reaching an estimated $44.09 billion in 2028 at a compound annual growth rate CAGR of 8.1%. This growth can be attributed to factors such as increasing demand for pharmaceuticals, rise in demand for medical devices, heightened consumer awareness about plastic packaging, regulatory compliance and sustainability initiatives, and a growing demand for lightweight packaging products from the consumer base. Major trends expected to drive this growth further in the forecast period include innovative packaging designs, advanced smart packaging technologies, innovations in eco-friendly packaging materials, advancements in plastic packaging technology, and innovations within the healthcare industry. You can get insights into more such trends by pre-booking the full report: What Are The Main Drivers For The Growth Of The Plastic Healthcare Packaging Market? The expansion of the pharmaceutical industry is expected to propel the growth of the plastic healthcare packaging market. This industry, which focuses on the research, development, manufacturing, and marketing of medications and drugs, is expanding due to factors such as the increasing aging population, longer life expectancy, and advances in medical science. Plastic healthcare packaging plays a critical role in supporting the pharmaceutical industry by ensuring product safety and integrity, enhancing patient convenience, reducing costs, and enabling drug delivery and administration innovation. To illustrate this, the total pharmaceutical production in Europe accounted for $384,200 million €340,000 million in 2022 according to the European Federation of Pharmaceutical Industries and Associations EFPIA, indicating an increase of approximately 4.95% from 366,267 million €323,950 million in 2021. Which Key Companies Are Playing A Major Role In The Plastic Healthcare Packaging Market? Major companies operating in the plastic healthcare packaging market include McKesson Corporation, Amcor Limited, Berry Global Group Inc., Mondi Group PLC, Sealed Air Corporation, Catalent Inc., Nipro Corporation, Aptar Group Inc., West Pharmaceutical Services, Tekni-Plex Inc., Gerresheimer AG, Constantia Flexibles Group, Klockner Pentaplast Group, Wipak Ltd., Comar LLC, Aphena Pharma Solutions Inc., Bilcare Limited, Adelphi Healthcare Packaging, Clondalkin Group, and Alexander James Corporation. In What Ways is the Plastic Healthcare Packaging Market Segmenting? The plastic healthcare packaging market can be segmented in the following ways: 1 By Type: Bottle Packaging, Blister Packaging, Syringes Packaging, Vial Packaging, Device Packaging, Other Types 2 By Material Type: Polyethylene, Polyvinyl Chloride, Polystyrene, Polypropylene, Polyethylene Terephthalate, Other Material Types 3 By Type Of Drug Delivery: Pulmonary, Oral drugs, Transdermal, Injectable, Nasal, Topical, Ocular 4 By End-User: Pharmaceutical Companies, Medical Device Manufacturing Companies, Other End-Users What can we expect from Different Regions in the Plastic Healthcare Packaging market? In 2023, North America was the largest region in the plastic healthcare packaging market. However, Asia-Pacific is expected to be the fastest-growing region during the forecast period. The regions covered in the plastic healthcare packaging market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. Browse Through More Similar Reports By The Business Research Company: Plasticizers Global Market Report 2024 Plastic Material And Resins Global Market Report 2024 Plastic Products Global Market Report 2024 About The Business Research Company Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game. Contact us at: The Business Research Company: Americas +1 3156230293 Asia +44 2071930708 Europe +44 2071930708 Email us at ... Follow us on: LinkedIn: YouTube: Global Market Model: global-market-model Oliver Guirdham The Business Research Company +44 20 7193 0708 email us here Visit us on social media: Facebook X LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above. MENAFN15122024003118003196ID1108995438 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

"The Goddess" delves into the universal themes of love, loss, and redemption, resonating with audiences of all backgrounds and nationalities. Through the mesmerizing performances of Sophie Marceau and the sublime direction of Zhang Yimou, the film transcends linguistic barriers and cultural differences, speaking directly to the hearts of viewers around the world. It is a testament to the transformative power of cinema, which has the ability to forge connections and foster empathy among people from diverse walks of life.'Explain It to Our Faces': Victims' Families React to Biden's Death Row Clemency

The Blackhawks claimed they would replace injured defenseman Seth Jones by committee, but aside from bumping every healthy defenseman one rung up the depth chart out of necessity, they actually haven’t. Instead, young Alex Vlasic has taken over Jones’ role, operating as the Hawks’ No. 1 defensemen during five-on-five play and quarterbacking the first power-play unit (although the Hawks have drawn very few opportunities). In the four games missed so far by Jones, the NHL’s time-on-ice leader before he suffered a right foot injury that will sideline him for another three-plus weeks, Vlasic has exceeded 23:30 of ice time every game and logged exactly 26:34 twice. “It’s definitely a big load to handle, but I feel like I’ve done a pretty good job,” Vlasic said Tuesday. “You’ve got to pick your spots jumping up in the play and make sure you’re not taking too long of shifts, especially against better teams, so you don’t get hemmed in.” This situation isn’t ideal for the Hawks right now, but it is excellent experience for Vlasic, whom the franchise will depend on to anchor their defense for years to come — regardless of whether he, Artyom Levshunov or someone else develops into their true No. 1 defenseman post-Jones. The 23-year-old Wilmette native is enjoying another stellar season despite the Hawks’ team struggles, even if he’s not quite as close to Superman as he imagined back in training camp. “In the ‘D'-zone in the beginning of the year...he had a couple hiccups,” assistant coach Kevin Dean said earlier this month. “He was [thinking], ‘I’m going to defend this guy and I’m going to take this pass away,’ and he wasn’t doing either. “He’s getting his brain around [the idea that], ‘I just do my job and do it well.’ And he’s terrific: He’s big; he’s smart; he’s athletic. He can skate, he can move pucks and his shot has really developed.” Vlasic unleashed a 101.9 mph shot — the fourth-hardest in the NHL this season — against the Ducks last week, rewarding him for his efforts this past summer to strengthen and improve his shooting . His hardest shot last season was 90.5 mph. “I noticed it before training camp, just stepping on the ice watching him: ‘Whoa, his shot [is good],’” Dean said. “Last year, he would take five shots, and two of them would be like, ‘Wow, that was really hard.’ ... But now he certainly seems more consistent.” The most important aspects where Vlasic can fill Jones’ shoes, however, are retrieving dump-ins and then exiting the defensive zone with possession. That can help the Hawks avoid getting stuck in the zone — a frequent problem for them. Vlasic has averaged 26.7 retrievals per 60 minutes this season, per All Three Zones. That’s one of the highest rates in the league. Jones (22.9) and Wyatt Kaiser (21.9) are the only other Hawks defensemen significantly above the league average of 19.9. Moreover, Vlasic and Jones have averaged 10.2 and 10.3 defensive-zone exits with possession per 60 minutes, respectively. They’re the only two Hawks defensemen significantly above the league average of 7.0 in that category. Dean has talked with Vlasic about the value of body position to help with both of those things. If an opposing forward skates behind the net to chase the puck, Vlasic can form a wall between the forward and the puck using his 6-6 frame alone. “He’s getting more comfortable using his body on the retrievals,” Dean said. “He’s a guy who can see the ice and can escape that forechecker to get time to make a play. He’s only going to get better with that, too. He’s not overthinking it. [When he identifies] the first option, it’s on and off his stick pretty well.” Defensive work In the defensive zone, Vlasic does have a tendency to believe he can do two things at once sometimes. The Hawks appreciate that confidence but are trying to convince him that’s not realistic; he’ll be best served focusing on defending one person at a time. Boxing out around the net has been one focus area. Earlier in the season, he would devote himself so wholeheartedly to boxing out that he would turn his back to the puck at the point and have no idea where the play was headed. "[I’m] learning how to box out while still having your head facing wherever the puck is,” Vlasic said. “You might have to let that guy go if the puck comes to you or if the [point] guy starts skating down at you, if your forward gets beat. Because we don’t play man-on-man in the D-zone, [you have to] make sure you’re not solely focusing on one guy.” There are situations, however, where he shouldn’t leave the net-front guy to cover a defenseman skating down. The Flyers’ first goal Saturday against the Hawks was one such scenario: Vlasic stopped boxing out Sean Couturier to react to wide-open Rasmus Ristolainen receiving the puck on the weak side, and then Ristolainen fed Couturier for a simple tap-in. “It’s very situational where you have to realize if the guy has a good angle or if he has a lot of time,” Vlasic said. “It’s a gray area for sure, but that specific time, I might just have to recognize that we’ll give up that shot from way outside the dot and make sure nothing goes across the crease.” Dean has also emphasized to Vlasic the importance of going through opposing forwards’ hands when trying to dispossess them. Vlasic’s ultra-long stick and reach makes him elite at poke-checks, but the Hawks don’t want him to rely solely on that approach. “Sometimes I get away with that, but when you go against guys that are good at puck-protecting and have big, strong frames, if you just go for the puck, they’ll be able to shield it away from you,” Vlasic said. "[You have to] make sure you’re always trying to go through the hands first and follow through with the stick.”

It’s been a long time since Sega has touched the Virtua Fighter franchise. While players aren’t getting a new entry in the fighting game franchise (although maybe they should), the series is making a small comeback on Steam this winter. Sega made an announcement on X Friday that Virtua Fighter 5 R.E.V.O, an upgraded version of the 3D fighter Virtua Fighter 5 Ultimate Showdown , is now available to wishlist on Steam . More details will be shared at a later date, but for now, we know that it’ll be playable in 4K resolution and up to 60 frames per second, will have gameplay balance tweaks, upgraded visuals, and, best of all for fighting game fans, rollback netcode, so there won’t be any latency regardless of your platform. It’ll also feature new online modes that’ll allow up to 16 players to compete. Virtua Fighter is one of those somewhat forgotten arcade fighting game franchises , not getting as much love as Street Fighter or Mortal Kombat. There were five main entries, and the last one, Virtua Fighter 5 , came out in 2006. It’s been re-released a few times since then, with Virtua Fighter 5 Ultimate Showdown launching in 2021 and bringing new music and updated graphics to PlayStation 4. That does mean you can still play Virtua Fighter 5 if you have a PlayStation Network account, and it’s still one of the best fighting games for the PS5 . R.E.V.O is sort of a PC port of this version, but with more modern features. Sega isn’t giving up on Ultimate Showdown though. Gematsu reports that a 2.0 balance update is coming to Ultimate Showdown when R.E.V.O releases. If that’s still not enough for Virtua Fighter fans, this is a good reminder that there’s a nearly complete version of Virtua Fighter 5 inside Yakuza: Like a Dragon and Yakuza 6 . A version of Virtua Fighter 2 is also available on Steam for just $1.For investors, the surge in gold prices presents a lucrative opportunity to capitalize on the rising demand for this precious metal. Whether through physical gold purchases, gold-backed securities, or other investment vehicles, individuals and institutions can leverage the current market conditions to diversify their portfolios and safeguard against economic uncertainties.

The cryptocurrency market was thrown into chaos as Bitcoin experienced a sudden price drop, leading to a cascade of liquidations that left approximately 570,000 traders with their positions forcibly closed. The unprecedented volatility in the market sent shockwaves across the industry, causing significant losses and sparking concerns about the future of digital assets.